Statistics suggest that 40 million people in the U.S. encompassing all age groups live with anxiety disorders and 15 million people suffer from depression. There are many different medications that mental health practitioners may prescribe to alleviate the symptoms of anxiety and depression. However, ineffective results or troubling side effects may pose a problem. Pharmaceutical researchers continually develop new formulations in hopes of creating better treatments.
Aloradine belongs to a class of medications known as pherines. These compounds are designed to affect specific areas in the brain without traveling through the circulatory system. The medication is able to accomplish the task by being taken in the form of a nasal spray. In this way, the chemical compounds target sensory neurons in nasal passages that are regulated by the hypothalamus and in the limbic system for the treatment of anxiety disorders. Clinical trials indicate that the formula provides fast-acting relief.
Bacterial colonies in the gastrointestinal tract have long been suspected of causing various medical problems that include anxiety. The prebiotic formula is categorized as a trans-galactooligosaccharide and has proven effective to reduce anxiety symptoms. The medication also reduces cortisol levels and desensitizes users in the face of negative stimuli by interacting with the hypothalamic-pituitary-adrenal axis.
BNC210 or IW-2143
Currently in clinical trials, the medication demonstrates powerful anti-anxiety effects without causing sedation, interfering with cognitive function or posing a threat of addiction. The promising pharmaceutical also does not seem to have a long list of harmful side effects. Some research suggests that the formula may have the ability to encourage neuron growth. Originally developed by Bionomics, the formula has been transferred to Ironwood Pharmaceuticals where is was renamed.
Augmented drugs are created by combining a medication with a chemical compounds or another medication to enhance the effects of the first drug. Researchers found that adding Abilify or Seroquel to antidepressant formulations to boost the end result.
The medication recently received approval for depression and is a modified form of trazodone. While alleviating symptoms of depression and anxiety, the pharmaceutical is also designed to elevate mood, improve appetite and increase energy levels. Oleptro acts by balancing serotonin levels in the brain.
The medication was approved in 2011 and acts by inhibiting dopamine, norepineprine and serotonin, which increases levels of the compounds between neurons and slows neuron firing. The drug is thought to be similar to buspirone.
Classified as a selective serotonin reuptake inhibitor, the medication interacts with five different types of receptors to inhibit acetylcholine, dopamine, norepinephrine and serotonin absorption in the front region of the brain. In this way, along with alleviating depression symptoms, the formula also corrects cognitive malfunction that may occur with the disorder. This effect has been of special interest in terms of treating elderly patients.